Understanding Group A Streptococcus in Children
Official title: Gene Expression in Isolates of Group A Streptococci Recovered From Patients Who Are Carriers
Run by University of Wisconsin, Madison · NCT01558804 · Data updated 2026-11-12
This study is trying to understand the differences in Group A strep bacteria between kids who are sick and those who carry the bacteria without symptoms, to help improve treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 5 Years to 15 Years |
| Sex | All |
| Enrollment | 180 (estimated) |
| Sponsor | University of Wisconsin, Madison Academic / other |
| Locations | 1 site (Madison, Wisconsin) |
| Status | Recruiting |
| Started | May 9, 2011 |
| Main results expected | June 2028 |
| Study ends | June 2028 |
| Registry record updated | February 18, 2026 |
| Trial ID | NCT01558804 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are children aged 5 to 15 years who have a positive rapid antigen detection test for Group A streptococcus.
✕Probably not a fit
Patients who are unable to take beta lactam antibiotics or have other concurrent bacterial infections may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This research aims to investigate the differences in Group A streptococcus (GAS) between children who are acutely infected and those who are carriers. The study will collect samples from children aged 5 to 15 years with acute pharyngitis and a positive test for GAS, comparing their transcriptional profiles and genetic sequences. By analyzing these samples, the researchers hope to uncover unique characteristics of GAS during acute infection versus carrier states, which could inform treatment approaches. The study will enroll approximately 180 participants to achieve its objectives.
Why it matters
Potential benefit: If successful, this study could lead to better understanding and management of streptococcal infections in children, potentially reducing unnecessary antibiotic use.
How similar studies have gone: While this study explores a specific aspect of GAS infection, similar studies have shown promise in understanding bacterial behavior and treatment outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Children ages 5-15 years * Positive rapid antigen detection test for group A streptococcus * Parent or legal guardian present and able to provide consent * Provider prescribes treatment with a beta lactam antibiotic * English speaking Exclusion Criteria: * Unable to take beta lactam antibiotics * Other concurrent bacterial infection, i.e., pneumonia
Where it's running
-
UW Health Pediatric Clinics
Madison, Wisconsin, United States Recruiting
Study contacts
- Principal investigator: Gregory DeMuri, MD — University of Wisconsin, Madison
- Study coordinator: Cherie Schommer, BA
- Email: schommer2@wisc.edu
- Phone: 608-262-2631
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
See if SalivIQ Strep A detects strep throat in kids and adults
This study tests whether the SalivIQ Strep A test can correctly identify Group A Streptococcus in people with suspected strep throat using saliva and throat swabs.
-
18F-FES PET/MRI to find hidden disease in invasive lobular breast cancer
This study tests whether adding 18F-FES PET/MRI can reveal more disease in lobular breast cancer than standard imaging alone.
-
Share or Not to Share: A Peer-Led Support Program for Caregivers of Autistic Young Adults
A group, peer-led program tests how six virtual sessions can support family caregivers of autistic young adults (ages 18–26) in navigating roles, sharing experiences, and planning for the future.
-
Decision-support tool to aid blood biomarker testing discussions in primary care
A brief tool is being tested to help primary care doctors talk with patients about blood biomarker testing for Alzheimer's disease and support shared decision-making.
-
Durvalumab plus histotripsy for intrahepatic cholangiocarcinoma
This study tests whether adding histotripsy to ongoing durvalumab helps people with advanced intrahepatic cholangiocarcinoma by boosting the immune response and checking safety.
-
Proton Therapy Treatment-Planning Software: Checking How Well RayStation and RayCare Work in Real Care
This study tests whether the RayStation 2025 and RayCare 2025 software upgrades reliably support delivering standard proton therapy to adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.